New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More

Intellia (NTLA) Soars 13% to Fresh High

By Angelica Ballesteros | October 21, 2025, 12:56 PM

We recently published 10 Big Names Beating Wall Street at its Own Game. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best performers on Monday.

Intellia Therapeutics soared to a new all-time high on Monday, despite the lack of catalysts to boost buying appetite.

During the session, the stock soared to its highest 52-week price of $27.98 before paring gains to end the day just up by 13.05 percent at $27.98 apiece.

Earlier this month, Intellia Therapeutics, Inc. (NASDAQ:NTLA) earned an overall bullish sentiment from two investment companies, on strong optimism for its earnings and hereditary angioedema (HAE) program.

In a market note earlier, JMP Securities gave an “outperform” rating for the stock with a price target of $33, or an upside potential of 17.9 percent from its latest closing price.

According to the investment firm, the company’s drug candidate, lonvo-Z, could capture a 19-percent market share and potentially translate to $2.8 billion market opportunity.

Intellia (NTLA) Soars 13% to Fresh High

Topline data are expected in the first half of 2026, while a biologics license application (BLA) is targeted to be submitted in the second half of 2026.

If and when approved by the Food and Drug Administration, Intellia Therapeutics, Inc. (NASDAQ:NTLA) is scheduled to launch the drug in the first half of 2027.

While we acknowledge the potential of NTLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News